Image Credit: STAT News

STAT+: Next-gen obesity treatment from Novo Nordisk misses mark in pivotal trial

Watchdoq December 20, 2024

Novo Nordisk’s next-gen obesity drug led patients to lose substantial weight, but fell short of expectations.